References

1. Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, et al. (2004) Trends in heart failure incidence and survival in a community-based population. JAMA 292: 344-350. View
2. Hogg K, Swedberg K, McMurray J (2004) Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis. J Am Coll Cardiol 43: 317-327. View
3. Kitaoka H, Takata J, Yabe T, Hitomi N, Furuno T, et al. (1999) Low dose dobutamine stress echocardiography predicts the improvement of left ventricular systolic function in dilated cardiomyopathy. Heart 81: 523-527. View
4. Scrutinio D, Napoli V, Passantino A, Ricci A, Lagioia R, et al. (2000) Lowdose dobutamine responsiveness in idiopathic dilated cardiomyopathy: relation to exercise capacity and clinical outcome. Eur Heart J 21: 927-934. View
5. Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS (2003) Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 107: 2900-2907. View
6. Pijls NH, Fearon WF, Tonino PA, Siebert U, Ikeno F, et al. (2010) Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study. J Am Coll Cardiol 56: 177-184. View
7. De Bruyne B, Fearon WF, Pijls NH, Barbato E, Tonino P, et al. (2014) Fractional flow reserve-guided PCI for stable coronary artery disease. N Engl J Med 371: 1208-1217. View
8. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, et al. (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62: e147-239. View
9. Carr JJ, Hendel RC, White RD, Patel MR, Wolk MJ, et al. (2013) 2013 appropriate utilization of cardiovascular imaging: a methodology for the development of joint criteria for the appropriate utilization of cardiovascular imaging by the American College of Cardiology Foundation and American College of Radiology. J Am Coll Radiol 10: 456-463. View
10. White RD, Patel MR, Abbara S, Bluemke DA, Herfkens RJ, et al. (2013) 2013 ACCF/ACR/ASE/ASNC/SCCT/SCMR appropriate utilization of cardiovascular imaging in heart failure: an executive summary: a joint report of the ACR Appropriateness Criteria ® Committee and the ACCF Appropriate Use Criteria Task Force. J Am Coll Radiol 10: 493-500. View
11. Naya M, Tamaki N2 (2014) Imaging of Myocardial Oxidative Metabolism in Heart Failure. Curr Cardiovasc Imaging Rep 7: 9244. View
12. Ishida Y, Yasumura Y, Nagaya N, Fukuchi K, Komamura K, et al. (1999) Myocardial imaging with 123I-BMIPP in patients with congestive heart failure. Int J Card Imaging 15: 71-77. View
13. Nishimura T (1999) beta-Methyl-p-(123I)-iodophenyl pentadecanoic acid single-photon emission computed tomography in cardiomyopathy. Int J Card Imaging 15: 41-48. View
14. Hendel RC, Berman DS, Di Carli MF, Heidenreich PA, Henkin RE, et al. (2009) ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009 Appropriate Use Criteria for Cardiac Radionuclide Imaging: A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the American Society of Nuclear Cardiology, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society of Nuclear Medicine. J Am Coll Cardiol 53: 2201-2229. View
15. Matsuo S, Nakae I, Tsutamoto T, Okamoto N, Horie M (2007) A novel clinical indicator using Tc-99m sestamibi for evaluating cardiac mitochondrial function in patients with cardiomyopathies. J Nucl Cardiol 14: 215-220. View
16. Matsuo S, Nakajima K, Kinuya S (2010) Clinical use of nuclear cardiology in the assessment of heart failure. World J Cardiol 2: 344-356. View
17. Schindler TH, Solnes L (2015) Role of PET/ CT for the Identification of Cardiac Sarcoid Disease. Ann Nucl Cardiol 1: 79-86.
18. van den Borne SW, Isobe S, Verjans JW, Petrov A, Lovhaug D, et al. (2008) Molecular imaging of interstitial alterations in remodeling myocardium after myocardial infarction. J Am Coll Cardiol 52: 2017-2028. View
19. Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, et al. (2003) Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 349: 1027-1035. View
20. Sciagrà R, Passeri A, Cipollini F, Castagnoli H, Olivotto I, et al. (2015) Validation of pixel-wise parametric mapping of myocardial blood flow with ¹³NH₃ PET in patients with hypertrophic cardiomyopathy. Eur J Nucl Med Mol Imaging 42: 1581-1588. View
21. Kasama S, Toyama T, Iwasaki T, Sumino H, Kumakura H, et al. (2014) European Journal of Nuclear Medicine and Molecular Imaging, 41.
22. Fukushima K, Javadi MS, Higuchi T, Bravo PE, Chien D, et al. (2012) Impaired global myocardial flow dynamics despite normal left ventricular function and regional perfusion in chronic kidney disease: a quantitative analysis of clinical 82Rb PET/CT studies. J Nucl Med 53: 887-893. View
23. Wieland DM, Wu J, Brown LE, Mangner TJ, Swanson DP, et al. (1980) Radiolabeled adrenergi neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med 21: 349-353. View
24. Carrió I, Cowie MR, Yamazaki J, Udelson J, Camici PG (2010) Cardiac sympathetic imaging with mIBG in heart failure. JACC Cardiovasc Imaging 3: 92-100. View
25. Jessup M, Brozena S (2003) Heart failure. N Engl J Med 348: 2007-2018. View
26. Merlet P, Valette H, Dubois-Randé JL, Moyse D, Duboc D, et al. (1992) Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 33: 471-477. View
27. Kasama S, Toyama T, Sumino H, Nakazawa M, Matsumoto N, et al. (2008) Prognostic value of serial cardiac 123I-MIBG imaging in patients with stabilized chronic heart failure and reduced left ventricular ejection fraction. J Nucl Med 49: 907-914. View
28. Kasama S, Toyama T, Kurabayashi M (2015) Serial ¹²³I-metaiodobenzylguanidine imaging predicts the risk of sudden cardiac death in patients with chronic heart failure. Int J Cardiol 179: 82-83. View
29. Merlet P, Benvenuti C, Moyse D, Pouillart F, Dubois-Randé JL, et al. (1999) Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 40: 917-923. View
30. Boogers MJ, Borleffs CJ, Henneman MM, van Bommel RJ, van Ramshorst J, et al. (2010) Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol 55: 2769- 2777. View
31. Fukuoka S, Hayashida K, Hirose Y, Shimotsu Y, Ishida Y, et al. (1997) Use of iodine-123 metaiodobenzylguanidine myocardial imaging to predict the effectiveness of beta-blocker therapy in patients with dilated cardiomyopathy. Eur J Nucl Med 24: 523-529. View
32. Kakuchi H, Sasaki T, Ishida Y, Komamura K, Miyatake K (1999) Clinical usefulness of 123I meta-iodobenzylguanidine imaging in predicting the effectiveness of beta blockers for patients with idiopathic dilated cardiomyopathy before and soon after treatment. Heart 81: 148-152. View
33. Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, et al. (2007) Evaluation of cardiac sympathetic nerve activity and left ventricular remodelling in patients with dilated cardiomyopathy on the treatment containing carvedilol. Eur Heart J 28: 989-995. View
34. Fujimoto S, Inoue A, Hisatake S, Yamashina S, Yamashina H, et al. (2004) Usefulness of 123I-metaiodobenzylguanidine myocardial scintigraphy for predicting the effectiveness of beta-blockers in patients with dilated cardiomyopathy from the standpoint of long-term prognosis. Eur J Nucl Med Mol Imaging 31: 1356-1361. View
35. Cohen-Solal A, Rouzet F, Berdeaux A, Le Guludec D, Abergel E, et al. (2005) Effects of carvedilol on myocardial sympathetic innervation in patients with chronic heart failure. J Nucl Med 46: 1796-1803. View
36. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, et al. (2003) Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure. J Nucl Med 44: 884-890. View
37. Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, et al. (2006) Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure. Heart 92: 625-630. View
38. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, et al. (2002) Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. J Nucl Med 43: 1279-1285. View
39. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, et al. (2005) Effects of nicorandil on cardiac sympathetic nerve activity after reperfusion therapy in patients with first anterior acute myocardial infarction. Eur J Nucl Med Mol Imaging 32: 322-328. View
40. Kasama S, Toyama T, Hatori T, Kumakura H, Takayama Y, et al. (2005) Comparative effects of nicorandil with isosorbide mononitrate on cardiac sympathetic nerve activity and left ventricular function in patients with ischemic cardiomyopathy. Am Heart J 150: 477. View
41. Matsuo S, Nakajima K (2015) Assessment of caxardiac sympathetic nerve function using 123I-meta-iodobenzylguanidinescintigraphy: Technical aspects and standardization. Ann Nucl Cardiol 1: 27-34. View
42. Nakajima K, Okuda K, Matsuo S, Yoshita M, Taki J, et al. (2012) Standardization of metaiodobenzylguanidine heart to mediastinum ratio using a calibration phantom: effects of correction on normal databases and a multicentre study. Eur J Nucl Med Mol Imaging 39: 113-119. View
43. Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, et al. (2010) Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 55: 2212-2221. View
44. Nakata T, Nakajima K, Yamashina S, Yamada T, Momose M, et al. (2013) A pooled analysis of multicenter cohort studies of (123)I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure. JACC Cardiovasc Imaging 6: 772-784. View
45. JCS Joint Working Group (2012) Guidelines for clinical use of cardiac nuclear medicine (JCS 2010) -digest version -. Circ J 76: 761-767. View
46. Feldman MD, Alderman JD, Aroesty JM, Royal HD, Ferguson JJ, et al. (1988) Depression of systolic and diastolic myocardial reserve during atrial pacing tachycardia in patients with dilated cardiomyopathy. J Clin Invest 82: 1661-1669. View
47. Hasenfuss G, Holubarsch C, Hermann HP, Astheimer K, Pieske B, et al. (1994) Influence of the force-frequency relationship on haemodynamics and left ventricular function in patients with non-failing hearts and in patients with dilated cardiomyopathy. Eur Heart J 15: 164-170. View
48. Kim IS, Izawa H, Sobue T, Ishihara H, Somura F, et al. (2002) Prognostic value of mechanical efficiency in ambulatory patients with idiopathic dilated cardiomyopathy in sinus rhythm. J Am Coll Cardiol 39: 1264-1268. View
49. Nagaoka H, Isobe N, Kubota S, Iizuka T, Imai S, et al(1997) Myocardial contractile reserve as prognostic determinant in patients with idiopathic dilated cardiomyopathy without overt heart failure. Chest 111: 344-350. View
50. Ohshima S, Isobe S, Izawa H, Nanasato M, Ando A, et al. (2005) Cardiac sympathetic dysfunction correlates with abnormal myocardial contractile reserve in dilated cardiomyopathy patients. J Am Coll Cardiol 46: 2061- 2068. View
51. Kobayashi M, Izawa H, Cheng XW, Asano H, Hirashiki A, et al. (2008) Dobutamine stress testing as a diagnostic tool for evaluation of myocardial contractile reserve in asymptomatic or mildly symptomatic patients with dilated cardiomyopathy. JACC Cardiovasc Imaging 1: 718-726. View
52. Ohshima S, Isobe S, Hayashi D, Abe S, Kato K, et al. (2013) Myocardial 123I-MIBG scintigraphy predicts an impairment in myocardial functional reserve during dobutamine stress in patients with idiopathic dilated cardiomyopathy. Eur J Nucl Med Mol Imaging 40: 262-270. View
53. Isobe S, Izawa H, Iwase M, Nanasato M, Nonokawa M, et al. (2005) Cardiac 123I-MIBG reflects left ventricular functional reserve in patients with nonobstructive hypertrophic cardiomyopathy. J Nucl Med 46: 909-916. View
54. Murray AJ, Edwards LM, Clarke K (2007) Mitochondria and heart failure. Curr Opin Clin Nutr Metab Care 10: 704-711. View
55. Chen LB (1988) Mitochondrial membrane potential in living cells. Annu Rev Cell Biol 4: 155-181. View
56. Konno N, Kako KJ (1991) Effects of hydrogen peroxide and hypochlorite on membrane potential of mitochondria in situ in rat heart cells. Can J Physiol Pharmacol 69: 1705-1712. View
57. Carvalho PA, Chiu ML, Kronauge JF, Kawamura M, Jones AG, et al. (1992) Subcellular distribution and analysis of technetium-99m-MIBI in isolated perfused rat hearts. J Nucl Med 33: 1516-1522. View
58. Chiu ML, Kronauge JF, Piwnica-Worms D (1990) Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium(I) in cultured mouse fibroblasts. J Nucl Med 31: 1646-1653. View
59. Schaper J, Froede R, Hein S, Buck A, Hashizume H, et al. (1991) Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy. Circulation 83: 504-514. View
60. Li QS, Frank TL, Franceschi D, Wagner HN Jr, Becker LC (1988) Technetium-99m methoxyisobutyl isonitrile (RP30) for quantification of myocardial ischemia and reperfusion in dogs. J Nucl Med 29: 1539-1548. View
61. Fukushima K, Momose M, Kondo C, Higuchi T, Kusakabe K, et al. (2010) Myocardial 99mTc-sestamibi extraction and washout in hypertensive heart failure using an isolated rat heart. Nucl Med Biol 37: 1005-1012. View
62. Kawamoto A, Kato T, Shioi T, Okuda J, Kawashima T1, et al. (2015) Measurement of technetium-99m sestamibi signals in rats administered a mitochondrial uncoupler and in a rat model of heart failure. PLoS One 10: e0117091. View
63. Takeishi Y, Sukekawa H, Fujiwara S, Ikeno E, Sasaki Y, et al. (1996) Reverse redistribution of technetium-99m-sestamibi following direct PTCA in acute myocardial infarction. J Nucl Med 37: 1289-1294. View
64. Fujiwara S, Takeishi Y, Hirono O, Fukui A, Okuyama M, et al. (2001) Reverse redistribution of 99m Tc-sestamibi after direct percutaneous transluminal coronary angioplasty in acute myocardial infarction: relationship with wall motion and functional response to dobutamine stimulation. Nucl Med Commun 22: 1223-1230. View
65. Du B, Li N, Li X, Li Y, Hsu B (2014) Myocardial washout rate of resting ??mTc-Sestamibi (MIBI) uptake to differentiate between normal perfusion and severe three-vessel coronary artery disease documented with invasive coronary angiography. Ann Nucl Med 28: 285-292. View
66. Kumita S, Seino Y, Cho K, Nakajo H, Toba M, et al. (2002) Assessment of myocardial washout of Tc-99m-sestamibi in patients with chronic heart failure: comparison with normal control. Ann Nucl Med 16: 237-242. View
67. Takehana K, Maeba H, Ueyama T, Iwasaka T (2011) Direct correlation between regional systolic function and regional washout rate of ??mTcsestamibi in patients with idiopathic dilated cardiomyopathy. Nucl Med Commun 32: 1174-1178. View
68. Ikawa M, Kawai Y, Arakawa K, Tsuchida T, Miyamori I, et al. (2007) Evaluation of respiratory chain failure in mitochondrial cardiomyopathy by assessments of 99mTc-MIBI washout and 123I-BMIPP/99mTc-MIBI mismatch. Mitochondrion 7: 164-170. View
69. Carboni GP (2012) A novel clinical indicator using cardiac technetium-99m sestamibi kinetics for evaluating cardiotoxicity in cancer patients treated with multiagent chemotherapy. Am J Cardiovasc Dis 2: 293-300. View
70. Hayashi D, Ohshima S, Isobe S, Cheng XW, Unno K, et al. (2013) Increased (99m)Tc-sestamibi washout reflects impaired myocardial contractile and relaxation reserve during dobutamine stress due to mitochondrial dysfunction in dilated cardiomyopathy patients. J Am Coll Cardiol 61: 2007- 2017. View
71. Unno K, Isobe S, Izawa H, Cheng XW, Kobayashi M, et al. (2009) Relation of functional and morphological changes in mitochondria to myocardial contractile and relaxation reserves in asymptomatic to mildly symptomatic patients with hypertrophic cardiomyopathy. Eur Heart J 30: 1853-1862. View
72. Isobe S, Ohshima S, Unno K, Izawa H, Kato K, et al. (2010) Relation of 99mTc-sestamibi washout with myocardial properties in patients with hypertrophic cardiomyopathy. J Nucl Cardiol 17: 1082-1090. View
73. Somura F, Izawa H, Iwase M, Takeichi Y, Ishiki R, et al. et al. (2001) Reduced myocardial sarcoplasmic reticulum Ca(2+)-ATPase mRNA expression and biphasic force-frequency relations in patients with hypertrophic cardiomyopathy. Circulation 104: 658-663. View
74. Neubauer S (2007) The failing heart--an engine out of fuel. N Engl J Med 356: 1140-1151. View
75. Kimura Y, Kurzydlowski K, Tada M, MacLennan DH (1997) Phospholamban inhibitory function is activated by depolymerization. J Biol Chem 272: 15061-15064. View
76. Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D et al. (2000) PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101: 365-376. View
77. Yano M, Ono K, Ohkusa T, Suetsugu M, Kohno M, et al. (2000) Altered stoichiometry of FKBP12.6 versus ryanodine receptor as a cause of abnormal Ca(2+) leak through ryanodine receptor in heart failure. Circulation 102: 2131-2136. View
78. Ribeiro RF Jr, Potratz FF, Pavan BM, Forechi L, Lima FL, et al. (2013) Carvedilol prevents ovariectomy-induced myocardial contractile dysfunction in female rat. PLoS One 8: e53226. View
79. Yano M, Matsuzaki M (2001) [RyR-bound FKBP12.6 and the modulation]. Clin Calcium 11: 743-748. View